ABSTRACT

Objective: To examine the predictive role of insomnia and sleep duration on the 2-year course of depressive and anxiety disorders.

Method: This study is a secondary data analysis based on data from the baseline (2004–2007) and 2-year assessment of the Netherlands Study of Depression and Anxiety. Participants were 1,069 individuals with DSM-IV-based depressive and/or anxiety disorders at baseline. Sleep measures included insomnia (Women's Health Initiative Insomnia Rating Scale score ≥ 9) and sleep duration (categorized as short [≤ 6 hours], normal [7–9 hours], or long [≥ 10 hours]). Outcome measures were persistence of DSM-IV depressive and anxiety disorders (current diagnosis at 2-year follow-up), time to remission, and clinical course trajectory of symptoms (early sustained remission, late remission/recurrence, and chronic course). Logistic regression analyses were adjusted for sociodemographic characteristics and chronic medical disorders, psychotropic medications, and severity of depressive and anxiety symptoms.

Results: The effect of insomnia on persistence of depressive and/or anxiety disorders (OR = 1.50; 95% CI, 1.16–1.94) was explained by severity of baseline depressive/anxiety symptoms (adjusted OR with severity = 1.04; 95% CI, 0.79–1.37). Long sleep duration was independently associated with persistence of depression/anxiety even after adjusting for severity of psychiatric symptoms (OR = 2.52; 95% CI, 1.27–4.99). For short sleep duration, the independent association with persistence of combined depression/anxiety showed a trend toward significance (OR = 1.32; 95% CI, 0.98–1.78), and a significant association for the persistence of depressive disorders (OR = 1.49; 95% CI, 1.11–2.00). Both short and long sleep duration were independently associated with a chronic course trajectory (short sleep: OR = 1.50; 95% CI, 1.04–2.16; long sleep: OR = 2.91, 95% CI, 1.22–6.93).

Discussion: Both short and long sleep duration—but not insomnia—are important predictors of a chronic course, independent of symptom severity. It is to be determined whether treating these sleep conditions results in more favorable outcomes of depression and anxiety.


Submitted: July 25, 2012; accepted June 18, 2013.
Corresponding author: Josine G. van Mill, MD, Department of Psychiatry, A. J. Ernststraat 1187, 1081 HL, Amsterdam, The Netherlands (j.vanmarill@ggzingeest.nl).

© 2013 COPYRIGHT PHYSICIANS POSTGRADUATE PRESS, INC. NOT FOR DISTRIBUTION, DISPLAY, OR COMMERCIAL PURPOSES.

O R I G I N A L R E S E A R C H

Sleep Duration, but Not Insomnia, Predicts the 2-Year Course of Depressive and Anxiety Disorders

Josine G. van Mill, MD; Nicole Vogelzangs, PhD; Eus J. W. van Someren, PhD; Witte J. G. Hoogendijk, MD, PhD; and Brenda W. J. H. Penninx, PhD

The course of depressive and anxiety disorders is often chronic or marked by episodes of both remission and recurrence. Depression and anxiety disorders are associated with a significant comorbidity, impaired occupational functioning, and diminished quality of life; thus, it is of great importance to identify factors that determine their course.

Sleep may impact the course of depressive and anxiety disorders, given the intricate relationship between sleep disturbances and psychopathology. Sleep can be disturbed in terms of subjective quality (insomnia) and duration. Many studies have examined the role of insomnia on the outcome of depression. Currently, the term insomnia is usually reserved for a disorder in which subjects experience problems falling asleep combined with impairments in daytime functioning.

In individuals with major depression (n = 1,801; 1-year follow-up), remission rates were lower in those with insomnia. Depressed adolescents with insomnia (n = 309, 9 weeks’ follow-up) responded slower to antidepressants than adolescents without insomnia. For anxiety disorders, few studies have examined the impact of sleep on its course. One study (n = 533, 5-year follow-up) found no effect of insomnia on generalized anxiety disorder, panic disorder, or social phobia. In contrast, another study found that insomnia was associated with a better outcome in subjects with generalized anxiety disorder treated with venlafaxine. To our knowledge, no studies have examined sleep duration as predictor of course of depressive or anxiety disorders.

However, not all aspects of the relationship between sleep disturbances and the course of depressive/anxiety disorders have been studied extensively. In particular, the following factors need to be addressed: First, depressive and anxiety disorders should be studied simultaneously, because of frequent comorbidity between these disorders. Second, severity of psychopathology should be considered when studying the impact of sleep disturbances, because sleep disturbances can be a symptom of psychopathology. Third, the effects of insomnia and sleep duration need to be examined separately because of differential associations with psychopathology. Finally, sleep is also influenced by other factors, such as age, gender, chronic medical disorders, and use of (psychotropic) medication.

Many studies include some of the above-mentioned characteristics, but most include only individuals with major depression. For anxiety disorders, there are only a few studies available on the impact of sleep disturbances on course of illness. Also, there are a very limited number of studies that include data on both insomnia and sleep duration.

In this study, we examined the predictive role of sleep disturbances (both insomnia and duration) on the 2-year course of depressive and/or anxiety disorders in a sample of currently depressed and/or anxious patients, taking into account the effect of chronic
Both short and long sleep duration are important predictors of a chronic course of depressive and/or anxiety disorders.

Clinicians should routinely ask for sleep duration in depressed or anxious patients.

Medical disorders, psychotropic medication, and severity of psychopathology.

**METHOD**

**Sample**

Data were analyzed from the baseline and 2-year assessment of the Netherlands Study of Depression and Anxiety (NESDA), an ongoing longitudinal cohort study investigating the course of depressive and anxiety disorders (N = 2,981). Subjects were recruited from the general population (n = 564), primary health care (n = 1,610), and secondary mental health care (n = 807) in order to represent various care settings and psychopathology. Exclusion criteria for the NESDA study were inability to speak the Dutch language or presence of a known primary clinical diagnosis of bipolar disorder, severe addiction disorder, psychotic disorder, or organic psychiatric disorder. A detailed description of the study’s rationales, methods, and recruitment strategy is described elsewhere. The research protocol was approved by the ethical committees of participating universities, and all respondents provided written informed consent. Our sample was restricted to subjects with baseline depressive (major depressive disorder and dysthymia) or anxiety disorders (panic disorder, agoraphobia, social phobia, and generalized anxiety disorder), according to the Composite International Diagnostic Interview, version 2.1 (CIDI). The standardized diagnostic CIDI interview uses the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), criteria to establish diagnoses. A baseline disorder was defined as a 6-month CIDI depressive and/or anxiety diagnosis, with symptoms in the last month confirmed according to either the CIDI recency questions or the Life Chart Interview (see Course Outcomes below). Of the 1,456 baseline depressed or anxious individuals, 1,209 participated in the follow-up interview (83.0%). Nonresponse was higher in those with younger age, lower education, or depressive disorder. Subsequently, 140 individuals were excluded because of missing data on sleep measures (n = 124) or on outcome measures (n = 16), resulting in a final sample size of 1,069. Excluded individuals were more often male (P = .04), but they did not differ in age (P = .09), education level (P = .33), or presence of depressive, anxiety, or comorbid disorder.

**Measurements**

The baseline interview was conducted between 2004 and 2007, with follow-up interviews 2 years later.

**Insomnia and Sleep Duration**

Sleep was measured at baseline. Insomnia was measured with the Women’s Health Initiative Insomnia Rating Scale, which consists of 5 questions concerning sleep in the past 4 weeks (trouble falling asleep, waking up during the night, early morning awakenings, getting back to sleep after waking up, and sleep quality). Answers are on a 4-point scale, with a maximum score of 20. A higher score indicates more insomnia. In our study sample, Cronbach α was 0.83. Scores were dichotomized at a cutoff point of 9 or higher, which indicates clinically significant insomnia. We also used the total continuous score (range, 0–20). Sleep duration (in full hours, regarding the past 4 weeks) was estimated by the subjects. It was used as a categorical measure (short sleep duration ≤ 6 hours, normal sleep duration 7–9 hours, and long sleep duration ≥ 10 hours) and as a continuous measure.

**Course Outcomes**

Three course outcome measures were used: (1) persistence of diagnosis, (2) time to remission, and (3) clinical course trajectories of symptoms. Persistence of depressive/anxiety disorders was defined as a CIDI 6-month diagnosis of depressive and/or anxiety disorder at follow-up. Time to remission and clinical course trajectory of symptoms over the 2 years were defined by completing the Life Chart Interview for individuals with detected symptoms at the 2-year CIDI interview. By using a calendar method, life events were recalled to refresh memory, after which presence of depressive and anxiety symptoms was determined for each month during the previous 2 years. For each month with reported symptoms, severity was assessed (no or minimal, mild, moderate, severe, or very severe). Symptoms on LCI were considered to be present when a rating of at least mild severity was reported. Time to remission of the index disorder was defined as the first point in time (calculated in months) at which no symptoms of the disorder were reported over 3 consecutive months, based on the LCI. Using both the CIDI and the LCI, we defined 3 clinical course trajectories: (1) early sustained remission (remission within 6 months, no recurrence of symptoms during follow-up), (2) late remission/recurrence (remission after 6 months without recurrence, or remission with recurrence of depressive/anxiety symptoms after initial remission), and (3) chronic course (no remission, depressive/anxiety symptoms of at least mild severity during the whole follow-up period). Remission was defined as reporting no symptoms on the LCI for 3 consecutive months.

**Baseline Covariates**

Sociodemographic characteristics and chronic medical disorders. Sociodemographic characteristics included age, gender, and education (in years). Selected chronic medical disorders were based on our previous study on the association between sleep disturbances and psychopathology. Alcohol intake was categorized into none (less than 1 drink per week), moderate (males: 1–21 drinks per week; females: 1–14 drinks per week), or heavy (males: > 21 drinks per week; females: none).
Impact of Sleep on Course of Anxiety and Depression

> 14 drinks per week). Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. A total count of the following self-reported chronic diseases was made: lung disease, cancer, osteoarthritis, intestinal disorders, liver disease, epilepsy, chronic fatigue syndrome, thyroid gland disease, cardiovascular disease, and diabetes.

Psychotropic medication. Psychotropic medication influences sleep and the persistence of depressive and anxiety disorders. Antidepressant and benzodiazepine use in the past month was classified according to the World Health Organization’s Anatomical Therapeutic Chemical (ATC) classification.24 Antidepressants were categorized as selective serotonin reuptake inhibitors (ATC code N06AB), tricyclic antidepressants (ATC code N06AA), and other antidepressants (ATC codes N06AF and N06AX). For benzodiazepines, ATC codes NO5BA, NO5CF, NO5CD, and NO3AE were included.

Symptom severity. Severity of depressive symptoms was measured with the Inventory of Depressive Symptomatology (IDS).25 Because of overlap with our predictor variables, we excluded the 4 sleep-related items from the IDS, resulting in a maximum score of 72. The Cronbach α for this adjusted IDS scale was 0.83. Severity of anxiety symptoms was measured with the Beck Anxiety Inventory (BAI).26 The Cronbach α for the BAI was 0.90, and correlation between BAI and IDS was 0.61.

Statistical analyses. Data were analyzed using SPSS 15.0 (SPSS Inc, Chicago, Illinois). Baseline characteristics were calculated for the total sample and according to our main outcome measure, persistence of diagnosis. Differences between groups were compared on the basis of independent t tests for continuous variables and χ2 statistics for dichotomous/categorical variables. The cumulative probability of remission was estimated with Kaplan-Meier product limit. Subjects with a duration of symptoms greater than 24 months were censored at 24 months. Survival curves were compared across insomnia categories (yes/no) and sleep duration categories with the log-rank test.

Logistic regression analyses were performed, with sleep measures as the predictor and persistence of depressive and/or anxiety disorders as the outcome variable. First, analyses were adjusted for sociodemographic characteristics and chronic medical disorders (age, gender, education, alcohol intake, BMI, number of chronic medical disorders). Second, we also adjusted for psychotropic medication (antidepressants, benzodiazepines). Finally, we adjusted for all before-mentioned covariates (age, gender, education, alcohol intake, BMI, number of chronic medical disorders) and for severity of depressive (IDS) and anxiety (BAI) symptoms. In order to check whether the continuous measurement for sleep duration indeed showed a nonlinear association with course of depression/anxiety disorder, we performed an analysis while adding a sleep duration squared term (sleep duration × sleep duration) to the linear term. We also added both insomnia (categorical) and sleep duration (categorical) simultaneously to our first model (adjusting for age, gender, education, alcohol intake, BMI, and number of chronic medical disorders) to examine whether insomnia and sleep duration are independent predictors of course outcome. Finally, to rule out that insomnia and sleep duration may have an interacting effect, we tested whether an interaction term, insomnia (categorical) × sleep duration (categorical), did significantly predict persistence of diagnosis, adjusting for sociodemographic characteristics and chronic medical disorders.

Multinomial logistic regression analyses were performed with clinical course trajectories of symptoms as the outcome in which late remission/recurrence and chronic course were compared to early sustained remission. Analyses were also first adjusted for sociodemographic characteristics and chronic medical disorders, subsequently for psychotropic medication, and finally for severity of depressive (IDS) and severity of anxiety (BAI) symptoms. Also, additional fully adjusted (multinomial) logistic regression analyses were conducted to examine the association between sleep measures and persistence and the clinical course trajectories of depressive disorders and of anxiety disorders separately in order to investigate whether associations were consistent across depressive and anxiety disorder course. Again, analyses were conducted with both insomnia and sleep duration simultaneously in the fully adjusted model to check whether their effects were independent and with an interaction term for insomnia × sleep duration to check for potential interacting effects.

Finally, additional fully adjusted (multinomial) logistic regression analyses were conducted to examine the association between sleep measures and persistence and the clinical course trajectories of depressive disorders and of anxiety disorders separately, which allowed investigation of whether associations were consistent across depressive and anxiety disorder course.

RESULTS

Table 1 shows baseline characteristics of the study sample (N=1,069). The mean age was 42.7 years (SD = 12.3), and 59% of subjects reported insomnia. The mean sleep duration was 7.2 hours (SD = 1.4). Subjects with a persistent depressive/anxiety diagnosis reported more insomnia (63.2%) compared to subjects with no persistent disorder (52.4%, P < .001). Subjects with a persistent diagnosis also reported a shorter sleep duration (7.1 hours, SD = 1.5) compared to subjects with no persistent diagnosis (7.3 hours, SD = 1.3, P = .002), although both short and long sleep duration was more prevalent among the persistent group (P < .001). Figure 1 shows Kaplan-Meier survival curves for time to remission based on insomnia status and sleep duration. No differences in time to remission were found based on insomnia status (P = .18), but significant differences were found according to sleep duration status (P < .001). Subjects with a long sleep duration appeared to have the longest time to remission.

Persistence of Depressive and Anxiety Disorders Over 2 Years

Associations between sleep measures and persistence of depressive and/or anxiety disorders are described in Table 2.
At follow-up, 61.1% (n = 653) of the sample had a persistent diagnosis of depressive and/or anxiety disorder. Both insomnia and the continuous insomnia score were associated with persistence of depressive and/or anxiety disorders, after adjusting for sociodemographic characteristics, chronic medical disorders, and psychotropic medication (insomnia: OR = 1.48; 95% CI, 1.14–1.92; continuous score: OR = 1.04; 95% CI, 1.02–1.07). However, associations disappeared after adjusting for severity of depressive and anxiety symptoms.

Short sleep duration (as compared to normal sleep duration) was also associated with persistence of depressive and/or anxiety disorders, independent of sociodemographic characteristics, chronic medical disorders, and psychotropic medications (OR = 3.08; 95% CI, 1.59–5.95) and of severity of depressive and anxiety symptoms (OR = 2.52; 95% CI, 1.27–4.99). To determine whether the association between sleep duration and course outcome is indeed nonlinear, we assessed both the linear and the squared term for sleep duration in our analyses. The linear term was not associated with persistence of depressive and anxiety symptoms, but the squared term was (P = .02 after full adjustment), indicating a nonlinear association.

When adding insomnia (categorical) and sleep duration (categorical) simultaneously to our model (adjusting for age,
Figure 1. Survival Curves Illustrating Time to Remission for Depressive and Anxiety Disorders According to Insomnia Status and Sleep Duration (n = 1,066)a

A. Insomnia Status

B. Sleep Duration

Proportion of Subjects Reporting Symptoms to Fulfill Criteria of Depressive/Anxiety Disorder

Log-rank $\chi^2 = 18.3, P < .001$

1.0

0.8

0.6

0.4

0.2

0.0

0 6 12 18 24

Duration, mo

Log-rank $\chi^2 = 1.82, P = .18$

1.0

0.8

0.6

0.4

0.2

0.0

0 6 12 18 24

Duration, mo

Solid black lines are projected lines, since by definition no remission could have occurred within the first 3-month period. Three subjects were excluded because of missing data.

Table 2. Odds Ratios for Associating Sleep Measures With 2-Year Persistence and Clinical Course Trajectories in Depressed/Anxious Subjects (N = 1,069)

<table>
<thead>
<tr>
<th>Measure</th>
<th>Persistence of Diagnosisa (n = 653)</th>
<th>Course Trajectories of Symptomsb (n = 659)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td></td>
<td>$P$</td>
<td>$P$</td>
</tr>
<tr>
<td>Insomnia (yes/no)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sociodemographic characteristics plus CMD adjusted</td>
<td>1.50 (1.16–1.94) .002</td>
<td>1.16 (0.83–1.62) .38</td>
</tr>
<tr>
<td>Plus psychotropic medications adjusted</td>
<td>1.48 (1.14–1.92) .003</td>
<td>1.14 (0.82–1.59) .44</td>
</tr>
<tr>
<td>Plus severity adjusted</td>
<td>1.04 (0.79–1.37) .79</td>
<td>0.87 (0.61–1.24) .44</td>
</tr>
<tr>
<td>Insomnia (continuous)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sociodemographic characteristics plus CMD adjusted</td>
<td>1.04 (1.02–1.07) .002</td>
<td>1.03 (1.00–1.06) .09</td>
</tr>
<tr>
<td>Plus psychotropic medications adjusted</td>
<td>1.04 (1.02–1.07) .003</td>
<td>1.03 (1.00–1.06) .11</td>
</tr>
<tr>
<td>Plus severity adjusted</td>
<td>1.01 (0.97–1.03) .96</td>
<td>0.99 (0.96–1.04) .96</td>
</tr>
<tr>
<td>Sleep duration (categories)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sociodemographic characteristics plus CMD adjusted</td>
<td>1.64 (1.24–2.17) .001</td>
<td>1.48 (1.02–2.15) .04</td>
</tr>
<tr>
<td>Short sleep duration</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Normal sleep duration</td>
<td>3.31 (1.72–6.37) &lt;.001</td>
<td>2.04 (1.03–5.00) .12</td>
</tr>
<tr>
<td>Plus psychotropic medications adjusted</td>
<td>1.66 (1.25–2.21) &lt;.001</td>
<td>1.50 (1.03–2.18) .03</td>
</tr>
<tr>
<td>Short sleep duration</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Normal sleep duration</td>
<td>3.08 (1.59–5.95) .001</td>
<td>1.91 (0.77–4.71) .16</td>
</tr>
<tr>
<td>Plus severity adjusted</td>
<td>1.32 (0.98–1.78) .06</td>
<td>1.28 (0.87–1.88) .20</td>
</tr>
<tr>
<td>Normal sleep duration</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Long sleep duration</td>
<td>2.52 (1.27–4.99) .008</td>
<td>1.64 (0.66–4.10) .29</td>
</tr>
<tr>
<td>Sleep duration (continuous)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sociodemographic characteristics plus CMD adjusted</td>
<td>Linear duration .09</td>
<td>0.99 (0.88–1.12) .92</td>
</tr>
<tr>
<td></td>
<td>Squared duration .01</td>
<td>1.13 (1.03–1.23) .006</td>
</tr>
<tr>
<td>Plus psychotropic medications adjusted</td>
<td>0.91 (0.82–1.00) .04</td>
<td>0.98 (0.87–1.11) .76</td>
</tr>
<tr>
<td>Linear duration</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td></td>
<td>Squared duration .01</td>
<td>1.12 (1.03–1.22) .009</td>
</tr>
<tr>
<td>Plus severity adjusted</td>
<td>Linear duration .07</td>
<td>1.03 (0.91–1.17) .66</td>
</tr>
<tr>
<td></td>
<td>Squared duration .01</td>
<td>1.09 (1.00–1.19) .07</td>
</tr>
</tbody>
</table>

aBased on logistic regression analyses, adjusted for sociodemographic characteristics and chronic medical disorders (age, gender, education, alcohol intake, body mass index, number of chronic medical disorders), psychotropic medications (antidepressants, benzodiazepines), and severity of symptoms (Inventory of Depressive Symptomatology and Beck Anxiety Inventory).

bBased on multinomial logistic regression analyses, reference category equals “early sustained remission” (n = 266), adjusted for sociodemographic characteristics and health (age, gender, education, alcohol intake, body mass index, number of chronic medical disorders), psychotropic medications (antidepressants, benzodiazepines), and severity of symptoms (Inventory of Depressive Symptomatology and Beck Anxiety Inventory).

cOnly linear sleep duration term included.

dIncludes both linear and squared sleep duration term.

Abbreviation: CMD = chronic medical disorders.
Table 3. Odds Ratios for Associating Sleep Measures With Persistence of Diagnosis and Chronic Course of Symptoms for Depressive and Anxiety Disorders Separately (N = 1,069)

<table>
<thead>
<tr>
<th>Sleep measure</th>
<th>Persistence of Diagnosisa</th>
<th>Chronic Course of Symptomsb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Depressive Disorder (n = 424)</td>
<td>Anxiety Disorder (n = 492)</td>
</tr>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td>Insomnia (yes/no)</td>
<td>1.27 (0.95–1.70)</td>
<td>.10</td>
</tr>
<tr>
<td>Insomnia (continuous)</td>
<td>1.02 (1.00–1.05)</td>
<td>.11</td>
</tr>
<tr>
<td>Sleep duration (categories)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short sleep duration</td>
<td>1.49 (1.11–2.00)</td>
<td>.008</td>
</tr>
<tr>
<td>Normal sleep duration</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Long sleep duration</td>
<td>2.52 (1.40–4.54)</td>
<td>.002</td>
</tr>
<tr>
<td>Sleep duration (continuous)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Linear duration</td>
<td>0.98 (0.88–1.08)</td>
<td>.62</td>
</tr>
<tr>
<td>Squared duration</td>
<td>1.11 (1.04–1.18)</td>
<td>.002</td>
</tr>
</tbody>
</table>

aBased on logistic regression analyses, adjusted for age, gender, education, alcohol intake, body mass index; number of chronic medical disorders, antidepressants, benzodiazepines, and severity of symptoms (Inventory of Depressive Symptomatology and Beck Anxiety Inventory).
bBased on multinomial logistic regression analyses comparing chronic course versus early sustained remission; adjusted for age, gender, education, alcohol intake, body mass index; number of chronic medical disorders, antidepressants, benzodiazepines, and severity of symptoms (Inventory of Depressive Symptomatology and Beck Anxiety Inventory).
cOnly linear sleep duration term included.
dIncluded both linear sleep duration term as well as squared sleep duration term.

If insomnia is associated with persistent diagnosis and/or chronic course of depressive symptoms, then it is likely that insomnia and sleep duration have independent effects on the outcome measures. Also, there was no significant interaction effect of the insomnia (categorical) × sleep duration (categorical) term (P = .34).

Course Trajectories of Symptoms Over 2 Years

Associations between sleep measures and clinical course trajectories of symptoms are described in Table 2. Insomnia was not associated with late remission/recurrence or a chronic course (as compared to early sustained remission) after adjusting for sociodemographic characteristics and chronic medical disorders (late remission/recurrence: OR = 1.44; 95% CI, 1.06–1.95; long sleep duration: OR = 3.37; 95% CI, 1.75–6.51). These analyses indicate that insomnia and sleep duration have independent effects on the outcome measures. Also, there was no significant interaction effect of the insomnia (categorical) × sleep duration (categorical) term (P = .34).

Course Outcomes for Depressive Versus Anxiety Disorders

To compare whether effects were comparable for depressive and anxiety disorders, we repeated the analyses for course outcomes for both disorders separately (Table 3). In our sample, 424 subjects had a persistent depressive disorder (with or without an anxiety disorder) and 492 subjects had a persistent anxiety disorder (with or without a depressive disorder). Insomnia (both dichotomous and continuous) was not associated with persistent depressive disorder, nor with persistent anxiety disorder. Both short and long sleep duration were independently associated with persistent depressive disorder (including severity of symptoms) after full adjustment (short sleep duration: OR = 1.49; 95% CI, 1.11–2.00; long sleep duration: OR = 2.52; 95% CI, 1.40–4.54). For anxiety disorders, we found no significant associations between sleep duration and persistence.

Furthermore, we explored the association of sleep measures with clinical course trajectories of depressive symptoms and of anxiety symptoms separately. Only results for chronic course are presented because the results for associating sleep measures with course of symptoms were not significantly different between early remission and remission/recurrence in our previous analyses (Table 2). Both insomnia and the insomnia continuous score were not associated with a chronic course of depressive symptoms, nor with a chronic course of anxiety symptoms. However, both short and long sleep duration were associated with a chronic course of depressive symptoms.
symptoms (short sleep duration: OR = 2.03; 95% CI, 1.21–3.39; long sleep duration: OR = 4.34; 95% CI, 1.51–12.46) as well as a chronic course of anxiety symptoms (short sleep duration: OR = 1.62; 95% CI, 1.05–2.50; long sleep duration: OR = 7.73; 95% CI, 1.76–33.95). A nonlinear association between sleep duration and chronic course of depressive as well as anxiety symptoms was again confirmed by significant associations between the squared sleep duration term and chronic course of symptoms (depressive symptoms: $P = .004$; anxiety symptoms: $P = .001$).

**DISCUSSION**

Our results clearly indicate that insomnia does not predict the course of depressive and/or anxiety disorders. However, both short sleep duration and long sleep duration do predict a poorer course in depressive and/or anxiety disorders. Our findings for insomnia are partially in line with earlier research. A large study ($N = 1,801$),$^9$ which controlled for severity of symptoms, found that subjects with insomnia were more likely to remain depressed. However, these were elderly primary care patients. Another study$^{16}$ found that insomnia alone was not predictive of nonremission in major depression, but the combination of insomnia and increased sleep latency was (while controlling for severity). In subjects with generalized anxiety disorder treated with venlafaxine or placebo, insomnia has been found to be predictive of a good outcome.$^{12}$ In general, results on the impact of insomnia on the persistence of depression/anxiety appear conflicting. One of the reasons for this may be the lack of a general definition of insomnia. All studies use different instruments in diagnosing insomnia, which hampers comparison. Also, insomnia may actually be an indicator of the underlying severity of psychiatric symptoms, with more severe psychopathology leading to more insomnia. Poor mental health has been shown to predict insomnia.$^{27,28}$ Moreover, insomnia has been shown to predict incident depression.$^{29}$ But it is also possible that the reverse is true, that more insomnia leads to more severe psychopathology. Because insomnia and psychopathology were measured at the same time, we cannot draw any causal conclusions on the link between insomnia and psychopathology.

Sleep duration showed a curvilinear association to course of psychopathology, with both short and long sleep duration being predictive of unfavorable course outcomes. Short sleep duration may increase daytime tiredness, which has been predictive of poor outcome of depression.$^{30}$ It is also possible that subjects reporting short sleep suffer from a biologically different type of depression or anxiety that might have a poorer course. A shared genetic background for mood disorders and short sleep has recently been proposed$^{31}$ because genetic variation previously linked to depression (GRIA3 polymorphism) has also been linked to shorter sleep duration. Or, short sleepers might simply have more time for pessimistic thoughts, thus contributing to poor outcome in depression.$^{30}$ Interestingly, long sleep duration also was predictive of a chronic course of depressive and anxiety disorders. Long sleep duration can be an atypical symptom of depression. Especially in atypical depression, a different psychopathology may exist, with more metabolic abnormalities and inflammation than in nonatypical depression,$^{32}$ which in turn could unfavorably impact the course of disorders.$^{33}$ Several studies have indeed indicated that underlying pathophysiology of inflammation may be more strongly involved than in the more typical (melancholic) depression.$^{34}$ Furthermore, higher levels of inflammation have also been associated with longer sleep duration itself.$^{35}$ It could well be that inflammation is an underlying common pathophysiologic mechanism leading to both increase in sleep duration and detrimental effects on course of depression/anxiety disorders. The same might hold true for anxiety disorders. Long sleep duration has also been correlated to low physical activity.$^{36}$ Individuals who spend many hours in their bed sleeping may be unsatisfied with being unable to activate themselves, resulting in increased feelings of depression and hopelessness, which may contribute to a poorer outcome.

Sleep duration, however, was a significant predictor of course of psychopathology, even after taking symptom severity into account. In a previous study,$^{16}$ an interaction effect between insomnia and short sleep duration predicted nonremission of depression. Interaction effects between insomnia and sleep duration have also been found to predict deficits in neuropsychological functioning,$^{37}$ hypertension,$^{38}$ type 2 diabetes,$^{39}$ and, in men, even increased mortality$^{40}$ suggesting that interaction effects between insomnia and sleep duration lead to adverse outcomes on multiple domains of health. However, our study could not confirm interaction effects between insomnia and sleep duration on the outcome of psychopathology.

Our results also show that it is important to differentiate between insomnia and sleep duration, since there was no interaction effect between insomnia and sleep duration. This finding agrees with previous research,$^{14}$ suggesting that psychopathology is differentially associated with insomnia and sleep duration. The predictive effect of insomnia on course of psychopathology can possibly be attributed to higher symptom severity. But it is also possible that more severe psychopathology causes more severe insomnia.

Strengths of our study are the longitudinal data on sleep disturbances and psychopathology, making it possible to draw conclusions on the predictive role of sleep disturbances on course. Furthermore, diagnoses were based on DSM-IV criteria, and we adjusted our results for psychotropic medications and severity of psychopathology. However, there are some limitations. Both insomnia and sleep duration were self-reported, and subjects with psychopathology may overestimate or underestimate their sleep. We did not use objective measures of sleep such as polysomnography or actigraphy. Finally, the subgroup of long sleepers was not a large group ($n = 64$).

To conclude, our study adds significant information on the impact of sleep disturbances on the course of psychopathology. Both short and long sleep duration—but not insomnia—are predictors of a chronic course, independent
of disorder symptom severity. In clinical practice, routinely asking for sleep duration might identify subjects at risk for a chronic course.

**Drug names:** venlafaxine (Effexor and others).

**Author affiliations:** Department of Psychiatry and the EMGO Institute for Health and Care Research (Drs van Mill, Vogelzangs, and Penninx); Neuroscience Campus Amsterdam (all authors), VU University Medical Center, Amsterdam; Department of Sleep and Cognition, Netherlands Institute for Neurosciences, and Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam (Dr van Someren); Department of Psychiatry, Erasmus Medical Center, Rotterdam (Dr Hoogendijk); and Department of Psychiatry, Leiden University Medical Center, Leiden, and Department of Psychiatry, University Medical Center Groningen, Groningen (Dr Penninx), The Netherlands.

**Potential conflicts of interest:** None reported.

**Funding/support:** This study was supported by an unrestricted educational grant (in 2007) from Servier to the research foundation of the department of Psychiatry VU Medical Center (Dr Hoogendijk). The infrastructure for the NESDA study (www.nesda.nl/nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-Mw, grant number 10-000-1062) and is supported by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Arkin, Leiden University Medical Center, GGZ Rivierduinen, University Medical Center Groningen, Lents, GGZ Friesland, GGZ Drenthe, and Scientific Institute for Quality of Healthcare [IQ healthcare]; Netherlands Institute for Health Services Research [NIVEL]; and Netherlands Institute of Mental Health and Addiction [Trimbos Institute]).

**Role of the sponsors:** Servier was not involved in the design and conduct of the study; collection, management, and interpretation of the data; nor in the preparation, review, or approval of the manuscript.

**REFERENCES**


